Recruiting

PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn

The purpose of this study is to determine if normally occurring variations in a specific gene called PTGS-1 are associated with an increased risk of narrowing of the ductus arteriosus from exposure to over-the-counter pain medicines (NSAIDs).

ClinicalTrials.gov IDNCT00710177

PhaseNot Applicable

Enrollment200

SponsorMedical College of Wisconsin

AgeNo minimum reported

SexALL

I'm interested View official listing

Conditions studied

Persistent Pulmonary Hypertension of the Newborn

About this study

Primary outcomes

To determine whether or not a variation in the prostaglandin G/H Synthase-1 gene contributes to the incidence of PPHN in infants who are exposed to NSAIDs in utero. (participants will be followed for the duration of hospital stay, an expected average of 3 weeks)

Eligibility information

Inclusion Criteria: * Infants born greater than or equal to 34 weeks gestational age diagnosed with PPHN and normal, healthy infants born greater than or equal to 34 weeks gestational age. Exclusion Criteria: * Patients will be excluded if they are diagnosed with lethal congenital anomalies * structural congenital heart disease except presence of patent ductus arteriosus (PDA) or patent foramen ovale * structural gastrointestinal tract abnormality that could interfere with meconium passage * congenital anomalies such as diaphragmatic hernia, Potter's syndrome, or pulmonary hypoplasia

Study locations

Children's Wisconsin, Milwaukee, Wisconsin 53226 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.